Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTX – Research Report) and Anavex Life Sciences (AVXL – Research Report).
BioNTech SE (BNTX)
J.P. Morgan analyst Jessica Fye upgraded BioNTech SE to Hold today and set a price target of $106.00. The company’s shares closed last Friday at $91.20, close to its 52-week low of $88.00.
According to TipRanks.com, Fye is ranked #1257 out of 8565 analysts.
Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $132.58, representing a 36.1% upside. In a report issued on October 16, HSBC also downgraded the stock to Hold with a $111.00 price target.
See today’s best-performing stocks on TipRanks >>
Anavex Life Sciences (AVXL)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences today and set a price target of $54.00. The company’s shares closed last Friday at $5.20, close to its 52-week low of $4.90.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Anavex Life Sciences with a $50.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNTX:
- Mixed Day for Vaccine Stocks as Terrible News Emerges
- Pfizer, BioNTech announce ‘positive’ topline data for combo flu/COVID vaccine
- BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
- BioNTech presents Phase 1/2 data update for BNT211 in advanced solid tumors
- BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
